Halozyme Therapeutics (HALO) revenue breakdown
By product, Royalties is the largest at 62% of fiscal 2025 revenue; Sales-based milestones grew fastest, 91% a year over 3 years.
Revenue by product
Fiscal years, as Halozyme Therapeutics reports them in its 10-K filings; fiscal 2025 total $1.4B.
| Products | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Royalties | — | $64M | $79M | $70M | $89M | $204M | $360M | $448M | $571M | $868M | 62% |
| Proprietary product sales | $16M | $15M | $15M | $17M | $17M | $23M | $73M | $131M | $167M | $195M | 14% |
| Bulk rHuPH20 sales | $37M | $35M | $13M | $49M | $39M | $81M | $82M | $115M | $86M | $133M | 10% |
| Sales-based milestones | — | — | — | — | — | — | $10M | — | $30M | $70M | 5% |
| Device partnered product sales | — | — | — | — | — | — | $36M | $55M | $51M | $49M | 3% |
| Event-based development and regulatory milestones and other fees | — | $16M | $16M | $6M | $70M | $42M | $59M | $69M | $72M | $47M | 3% |
| Upfront license and target nomination fees | — | $173M | $26M | $53M | $37M | $42M | $30M | $2M | $27M | $18M | 1% |
| Device licensing and development revenue | — | $12M | $2M | $2M | $1M | $1M | $10M | $10M | $11M | $17M | 1% |
| Sales-based milestones | — | — | — | — | $15M | $50M | — | — | — | — | — |
| Sales-based milestones | — | $1M | — | — | — | — | — | — | — | — | — |
| Sales of ENHANZE drug product | — | — | $460,000 | — | — | — | — | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for HALO.
Open HALO in InvestinglyQuestions
Where does Halozyme Therapeutics make its money?
In fiscal 2025, by product: Royalties $868M, Proprietary product sales $195M, Bulk rHuPH20 sales $133M, Sales-based milestones $70M, Device partnered product sales $49M.
From Halozyme Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.